309 related articles for article (PubMed ID: 9759581)
1. Adjuvant interferon treatment for melanoma.
Agarwala SS; Kirkwood JM
Hematol Oncol Clin North Am; 1998 Aug; 12(4):823-33. PubMed ID: 9759581
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
Crott R
Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
[TBL] [Abstract][Full Text] [Related]
3. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H
J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440
[TBL] [Abstract][Full Text] [Related]
5. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
6. Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS; Kirkwood JM
Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
9. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
10. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of cutaneous melanoma: the interferon debate.
Kefford RF
Ann Oncol; 2003 Mar; 14(3):358-65. PubMed ID: 12598338
[TBL] [Abstract][Full Text] [Related]
12. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
[TBL] [Abstract][Full Text] [Related]
14. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
[TBL] [Abstract][Full Text] [Related]
15. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
Wilson LS; Reyes CM; Lu C; Lu M; Yen C
Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott R; Ali F; Burdette-Radoux S
Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
[TBL] [Abstract][Full Text] [Related]
19. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
